Cells For Immunotherapy Engineered For Targeting Antigen Present Both On Immune Cells And Pathological Cells

Patent No. EP3105317 (titled "Cells For Immunotherapy Engineered For Targeting Antigen Present Both On Immune Cells And Pathological Cells") was filed by Cellectis on Feb 13, 2015. The application was issued on Sep 19, 2018.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
JAMES POOLEJun 19, 2019CARPMAELS & RANSFORD
SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBJun 19, 2019-

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3105317

CELLECTIS
Application Number
EP15706399A
Filing Date
Feb 13, 2015
Status
Opposition Rejected
Feb 4, 2022
Publication Date
Sep 19, 2018